An investigational treatment for Marfan syndrome is as effective as the standard therapy at slowing enlargement of the aorta, the large artery of the heart that delivers blood to the body, new research shows. The findings indicate a second treatment option for Marfan patients, who are at high risk of sudden death from tears in the aorta.
The results are being presented Nov. 18 at the American Heart Association's annual meeting in Chicago and will appear online the same day in the New England Journal of Medicine.
"For years, standard medical therapy for Marfan syndrome consisted of giving patients beta blockers, which lower heart rate and blood pressure, reducing stress on the wall of the aorta," said study co-author Alan C. Braverman, MD, a cardiologist at Washington University School of Medicine in St. Louis. "This new study suggests that we have a second option for patients that appears to be as effective as standard treatment."
The second option is Losartan, an angiotensin receptor blocker. Past research in mice and smaller clinical trials suggested that this class of drugs might actually be superior to beta blocker treatment for Marfan syndrome. Angiotensin receptor blockers commonly are prescribed to treat high blood pressure.
People with Marfan syndrome have weak connective tissues and tend to develop unusually long arms, legs and fingers. In addition to heart problems, patients often develop problems with the eyes, lungs, bones and joints. Patients with the condition are at high risk of sudden death from a tear in the aorta, also called an aortic dissection.
Though there is no cure for Marfan syndrome, treatment with beta blockers and preventive surgery to replace the section of the aorta adjacent to the heart has increased lifespan to near normal. But physicians have continued to look for more effective therapies, especially since some patients on beta blockers experience side effects such as tiredness and nausea.
So investigators in the Pediatric Heart Network of the National Institutes of Health (NIH), including Braverman and senior author Ronald V. Lacro, MD, a cardiologist at Harvard Medical School and Boston Children's Hospital, conducted a clinical trial comparing the beta blocker Atenolol with Losartan.
The study included 608 patients with Marfan syndrome at 21 medical centers nationwide. Patients were ages 6 months to 25 years and had enlarged aortas. Half of these participants were randomly given Losartan, the investigational treatment, and the other half received Atenolol, the standard therapy, but in higher doses than physicians typically prescribe to see if this would increase the beta blocker's effectiveness.
After following participants for three years, the investigators reported no differences between the two groups in the growth rate of the aorta. They further observed similar rates of tears in the aorta, similar numbers of surgeries required to repair these tears and no difference in the number of deaths between the two groups.
"This trial demonstrated that Marfan patients treated with either Atenolol or Losartan had very slow rates of aortic growth, and each group tolerated their medications well," said Braverman, who treats patients at Barnes-Jewish Hospital. "While beta blockers may be the gold standard for this condition, these results suggest we must use effective doses. This is also an important alternative therapy for the smaller number of patients who are intolerant to beta blockers."
Braverman also pointed out that ongoing research, including clinical trials currently underway, will continue to shed light on the different effects of these drugs. Investigators would like to determine whether factors such as a patient's genetic makeup, age and severity of disease favor one drug over the other, or a combination of the two.
This work was supported by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH), grant numbers U01 HL068269, U01 HL068270, U01 HL068279, U01 HL068281, U01 HL068285, U01 HL068292, U01 HL068290, U01 HL068288 and U01 HL085057, and the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development. Additional support provided by The Marfan Foundation, Merck & Co. Inc., and Teva Canada Limited.
Lacro RV, et al for the Pediatric Heart Network Investigators. Atenolol versus Losartan in children and young adults with Marfan syndrome. The New England Journal of Medicine. Nov. 18, 2014.
Washington University School of Medicine's 2,100 employed and volunteer faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children's hospitals. The School of Medicine is one of the leading medical research, teaching and patient-care institutions in the nation, currently ranked sixth in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children's hospitals, the School of Medicine is linked to BJC HealthCare.